Principles of a new treatment algorithm in multiple sclerosis

References

• Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain125(Pt 10), 2202–2212 (2002).
   PubMed Web of Science ®Google Scholar
• Filippi M, Bozzali M, Rovaris M et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain126(Pt 2), 433–437 (2003).
   PubMed Web of Science ®Google Scholar
• O’Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon β-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult. Scler.15(6), 728–734 (2009).
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS et al. Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67(7), 1242–1249 (2006).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357(9268), 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet374(9700), 1503–1511 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med.343(13), 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Kollman C, O’Connor P et al. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology66(5), 678–684 (2006).
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet370(9585), 389–397 (2007).
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain131(Pt 3), 808–817 (2008).
   PubMed Web of Science ®Google Scholar
• Tintoré M, Rovira A, Río J et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology67(6), 968–972 (2006).
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med.346(3), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Moraal B, Pohl C, Uitdehaag BM et al. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch. Neurol.66(11), 1345–1352 (2009).
   PubMedGoogle Scholar
• CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology59(7), 998–1005 (2002).
   PubMed Web of Science ®Google Scholar
• Le Page E, Edan G. Long-term experience with induction treatment regimens in multiple sclerosis. J. Neurol. Sci.277, S46–S49 (2009).
   Google Scholar
• Bogglid M. Immunosuppression followed by immunomodulation. J. Neurol. Sci.277, S50–S54 (2009).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet352(9139), 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• IFN β Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43(4), 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Hartung H, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360(9350), 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdová E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology45(7), 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther.109, 198–209 (2006).
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J et al. Efficacy of treatment of MS with IFN β-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology72(23), 1976–1983 (2009).
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B et al. 250 µg or 500 µg interferon β-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol.8(10), 889–897 (2009).
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sørensen PS, Christensen T et al. A randomized study of two interferon-β treatments in relapsing–remitting multiple sclerosis. Neurology66(7), 1056–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology59(10), 1496–1506 (2002).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P et al. Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet359(9316), 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon β-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol.7(10), 903–914 (2008).
   PubMed Web of Science ®Google Scholar
• Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and Phase III studies of interferon β products in the treatment of multiple sclerosis. Clin. Ther.25(1), 105–118 (2003).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 911–923 (2006).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Clifford DB, DeLuca A, Simpson DB et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol.9, 438–446 (2010).
   PubMed Web of Science ®Google Scholar
• Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann. Neurol.68(3), 271–274 (2010).
   PubMed Web of Science ®Google Scholar
• Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch. Neurol.67(8), 923–930 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufman MD, Lee R, Norton H. Course of relapsing–remitting multiple sclerosis before, during and after natalizumab. Mult. Scler. DOI: 10.1177/1352458510389103 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol.68(2), 186–191 (2011).
   PubMedGoogle Scholar
• Pascual AM, Téllez N, Boscá I et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult. Scler.15(11), 1303–1310 (2009).
   PubMed Web of Science ®Google Scholar
• Martinelli V, Radaelli M, Straffi L et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol. Sci.30(Suppl. 2), S167–S170 (2009).
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-β antibodies in multiple sclerosis. Eur. J. Neurol.12(11), 817–827 (2005).
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-β therapy in multiple sclerosis. Lancet Neurol.9(7), 740–750 (2010).
   PubMed Web of Science ®Google Scholar
• Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin. Ther.24(11), 1871–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr. Pract.12(5), 522–528 (2006).
   PubMedGoogle Scholar
• Aktas O, Küry P, Kieseier BC et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol.6, 373–382 (2010).
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov.9(11), 883–897 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue E, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 416–426 (2010).
   PubMed Web of Science ®Google Scholar
• Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs69(16), 2227–2243 (2009).
   PubMed Web of Science ®Google Scholar
• Warnke C, Hörste GM, Hartung HP et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr. Dis. Treat.5, 333–340 (2009).
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky J, Confavreux C et al. A placebo-controlled Phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes. Presented at: European Committee for Treatment and Research in Multiple Sclerosis. Göteborg, Sweden, 13–16 October, 2010.
   Google Scholar
• Wolinsky J, O’Connor P, Confavreux C et al. A placebo-controlled Phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: magnetic resonance imaging (MRI) outcomes. Presented at: European Committee for Treatment and Research in Multiple Sclerosis. Göteborg, Sweden, 13–16 October 2010.
   Google Scholar
• Hartung HP, Aktas O. Oral therapies for multiple sclerosis: are we there yet? Lancet Neurol.9, 454–457 (2010).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol.68(3), 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Limmroth V, Malessa R, Zettl UK et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon β therapies for relapsing–remitting multiple sclerosis. J. Neurol.254(1), 67–77 (2007).
   PubMed Web of Science ®Google Scholar
• Carrá A, Onaha P, Luetic G et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina. Eur. J. Neurol.15(4), 386–393 (2008).
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis. Mult. Scler.15(1), 50–58 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Imrey PB, Calabresi PA et al. Results of the Avonex Combination Trial (ACT) in relapsing–remitting MS. Neurology72(6), 535–541 (2009).
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Orefice G, Quarantelli M et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing–remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult. Scler.16(4), 450–454 (2010).
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol.9(4), 381–390 (2010).
   PubMed Web of Science ®Google Scholar
• Metz LM, Li D, Traboulsee A et al. Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult. Scler.15(10), 1183–1194 (2009).
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase 2, randomized, double-blind, placebo-controlled study. Neurology72(9), 806–812 (2009).
   PubMed Web of Science ®Google Scholar
• Smith DR, Weinstock-Guttman B, Cohen JA et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon β. Mult. Scler.11(5), 573–582 (2005).
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Mellgren SI, Svenningsson A et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon β-1a for treatment of relapsing–remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol.8(6), 519–529 (2009).
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Sørensen PS, Andersson M et al. Methylprednisolone in combination with interferon β-1a for relapsing–remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol.9(7), 672–680 (2010).
   PubMed Web of Science ®Google Scholar
• Havrdová E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol.8(3), 254–260 (2009).
   PubMed Web of Science ®Google Scholar
• Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sørensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur. J. Neurol.16(3), 420–423 (2009).
   PubMed Web of Science ®Google Scholar
• Belachew S, Phan-Ba R, Bartholomé E et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing–remitting multiple sclerosis. Eur. J. Neurol.18(2), 240–245 (2011).
   PubMed Web of Science ®Google Scholar
• Putzki N, Yaldizli O, Mäurer M et al. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur. J. Neurol.17(1), 31–37 (2010).
   PubMed Web of Science ®Google Scholar
• Sangalli F, Moiola L, Bucello S et al. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study. Neurol. Sci. DOI: 10.1007/s10072-010-0344-z (2010) (Epub ahead of print).
   Google Scholar
• Piehl F, Holmén C, Hillert J, Olsson T. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol. Sci. DOI: 10.1007/s10072-010-0345-y (2010) (Epub ahead of print).
   Google Scholar
• Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol. Sci. DOI: 10.1007/s10072-010-0348-8 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Aktas O, Kieseier BC, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci.33(3), 140–152 (2009).
   Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet372(9648), 1463–1472 (2008).
   PubMed Web of Science ®Google Scholar
• Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet371(9630), 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• Baker DP, Pepinsky RB, Brickelmaier M et al. PEGylated interferon β-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J. Interferon Cytokine Res.30(10), 777–785 (2010).
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial Investigators. Alemtuzumab vs interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359(17), 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar